Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from INSERM provide details of new studies and findings in the area of breast cancer
January 8th, 2009
"Our aim was to conduct an analytical validation in a routine laboratory setting of the cerb-B2/c-neu ELISA assay kit from Calbiochem (R) used to measure the extracellular domain (ECD) of HER2/neu in the serum of breast cancer patients. The evaluation was based on three different production lots used in a routine laboratory setting," researchers in Grenoble, France report. "The reference value was based on a population of 217 patients with breast cancer not overexpressing HER2. The detection limit, below that given by the manufacturer, was 0.34 ng ml(-1) and the quantification limit was 0.90 ng ml(-1). Reproducibility and repeatability were at least 95%, precision...
Source: Women's Health Weekly (2009-01-08)
|
